ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (AgeX),
a subsidiary of BioTime,
Inc. (NYSE American: BTX), announces that Chief Executive Officer
Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, is
participating in a fireside chat at Cell
& Gene Therapy CEO on Monday, September 25, 2017 in Boston.
Dr. West’s fireside chat will be at 3:00pm ET/12:00pm PT with J. Craig
Venter, Ph.D., Co-Founder and Executive Chairman of Human
Longevity, Inc. and founder of Celera Genomics and the J.
Craig Venter Institute. It will be moderated by David Grainger,
Ph.D., CEO of Methuselah
Health and Partner at Medicxi.
Cell & Gene Therapy CEO is an off-the-record networking forum that
brings together CEOs and decision makers in cell therapy, gene therapy,
and regenerative medicine. Intimate discussion panels, keynotes and
fireside chats feature thought leaders debating business model
efficiencies, financing, regulatory issues, market access and
reimbursement, novel partnerships, manufacturing, and delivery
challenges. Healthcare investors and leading researchers also
About AgeX Therapeutics
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American:
BTX), is a biotechnology company applying technology relating to
cellular immortality and regenerative biology to aging and age-related
diseases. The company has three initial areas of product development:
pluripotent stem cell-derived brown adipocytes (AGEX-BAT1); vascular
progenitors (AGEX-VASC1); and induced Tissue Regeneration (iTR). Initial
planned indications for these products are Type 2 diabetes, cardiac
ischemia, and cancer respectively. More information on AgeX can be found
on the company’s website at www.agexinc.com.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on developing
and commercializing products addressing degenerative diseases. The
Company’s current clinical programs are targeting three primary sectors,
aesthetics, ophthalmology and cell/drug delivery. Its clinical programs
are based on two platform technologies: pluripotent cells and cell/drug
delivery. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. The foundation of the Company’s cell
delivery platform is its HyStem® cell and drug delivery matrix
technology. BioTime also has significant equity holdings in two publicly
traded companies, Asterias Biotherapeutics, Inc. and OncoCyte
Corporation, and one private company, AgeX Therapeutics.
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotimeinc.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotimeinc.com.